Our study suggests that multimodal compounds with a receptor profile like HBK-15, i.e., targeting 5-HT1A and, to a lesser extent, 5-HT7 and D2 receptors, could be attractive therapeutic option for patients with generalized anxiety disorder. The gene discussed is HTR1A; the disease is generalized anxiety disorder.